651.2K XNAS Volume
XNAS 21 Mar, 2025 10:19 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 14 Mar 2025 | 2,500 | 271,510 (0%) | 0% | 6.3 | 15,800 | Common Stock |
| Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 2,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Michelle G. Burris | Director | Sale of securities on an exchange or to another person at price $ 7.19 per share. | 13 Mar 2025 | 36,291 | 15,394 (0%) | 0% | 7.2 | 260,932 | Common Stock |
| Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 7.59 per share. | 12 Mar 2025 | 53,000 | 69,690 (0%) | 0% | 7.6 | 402,270 | Common Stock |
| Peter M. Neupert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| Peter M. Neupert | Director | Sale of securities on an exchange or to another person at price $ 7.05 per share. | 10 Mar 2025 | 10,000 | 224,690 (0%) | 0% | 7.1 | 70,500 | Common Stock |
| Peter M. Neupert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.07 per share. | 10 Mar 2025 | 50,000 | 234,690 (0%) | 0% | 4.1 | 203,500 | Common Stock |
| Michael J. Pellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 23,726 | 23,726 | - | - | Stock Option (right to buy) | |
| Michael J. Pellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 15,394 | 69,690 (0%) | 0% | 0 | Common Stock | |
| Peter M. Neupert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 23,726 | 23,726 | - | - | Stock Option (right to buy) | |
| Peter M. Neupert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 15,394 | 184,690 (0%) | 0% | 0 | Common Stock | |
| Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 15,394 | 122,690 (0%) | 0% | 0 | Common Stock | |
| Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 23,726 | 23,726 | - | - | Stock Option (right to buy) | |
| Michelle G. Burris | Director | Sale of securities on an exchange or to another person at price $ 7.94 per share. | 04 Mar 2025 | 15,664 | 51,685 (0%) | 0% | 7.9 | 124,372 | Common Stock |
| Michelle G. Burris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 23,726 | 23,726 | - | - | Stock Option (right to buy) | |
| Michelle G. Burris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 15,394 | 67,349 (0%) | 0% | 0 | Common Stock | |
| Chad M. Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 355,000 | 2,931,701 (2%) | 0% | 0 | Common Stock | |
| Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 7.64 per share. | 04 Mar 2025 | 102,218 | 2,959,249 (2%) | 0% | 7.6 | 780,946 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 247,117 | 3,061,467 (2%) | 0% | 0 | Common Stock | |
| Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 36,145 | 2,814,350 (2%) | 0% | 7.0 | 252,654 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 81,206 | 2,850,495 (2%) | 0% | 7.0 | 566,818 | Common Stock |
| Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 40,044 | 607,710 (0%) | 0% | 7.0 | 279,507 | Common Stock |
| Julie Rubinstein | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 175,000 | 647,754 (0%) | 0% | 0 | Common Stock | |
| Julie Rubinstein | President and COO | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 19,461 | 588,249 (0%) | 0% | 7.0 | 136,032 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 355,000 | 1,376,180 (1%) | 0% | 0 | Common Stock | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 40,603 | 1,335,577 (1%) | 0% | 7.0 | 283,409 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 56,053 | 1,279,524 (1%) | 0% | 7.0 | 391,810 | Common Stock |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 99,976 | 353,721 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 7,085 | 346,636 (0%) | 0% | 7.0 | 49,453 | Common Stock |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 13,790 | 332,846 (0%) | 0% | 7.0 | 96,392 | Common Stock |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 150,024 | 150,024 | - | - | Stock Option (right to buy) | |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 109,973 | 437,388 (0%) | 0% | 0 | Common Stock | |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 41,600 | 395,788 (0%) | 0% | 7.0 | 290,368 | Common Stock |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 3,065 | 392,723 (0%) | 0% | 7.0 | 21,424 | Common Stock |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 165,027 | 165,027 | - | - | Stock Option (right to buy) | |
| Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 6,964 | 269,010 (0%) | 0% | 7.0 | 48,678 | Common Stock |
| Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 253 | 275,974 (0%) | 0% | 7.0 | 1,766 | Common Stock |
| Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.97 per share. | 04 Mar 2025 | 3,103 | 276,227 (0%) | 0% | 7.0 | 21,628 | Common Stock |
| Kyle Piskel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 125,000 | 279,330 (0%) | 0% | 0 | Common Stock | |
| Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 119,971 | 373,261 (0%) | 0% | 0 | Common Stock | |
| Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 180,029 | 180,029 | - | - | Stock Option (right to buy) | |
| Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 26,023 | 347,238 (0%) | 0% | 7.0 | 181,641 | Common Stock |
| Einterz Owen Katey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 15,394 | 72,629 (0%) | 0% | 0 | Common Stock | |
| Einterz Owen Katey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 23,726 | 23,726 | - | - | Stock Option (right to buy) | |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Feb 2025 | 186,080 | 2,762,781 (2%) | 0% | 6.3 | 1,176,026 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.46 per share. | 19 Feb 2025 | 186,080 | 2,576,701 (2%) | 0% | 8.5 | 1,574,237 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Feb 2025 | 99,107 | 2,675,808 (2%) | 0% | 6.3 | 626,356 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.44 per share. | 19 Feb 2025 | 99,107 | 2,576,701 (2%) | 0% | 8.4 | 836,463 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 186,080 | 99,107 | - | - | Stock Option (right to buy) | |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 99,107 | 0 | - | - | Stock Option (right to buy) | |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 100,287 | 2,676,988 (2%) | 0% | 6.3 | 633,814 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.44 per share. | 13 Feb 2025 | 100,287 | 2,576,701 (2%) | 0% | 8.4 | 846,422 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 158,921 | 2,735,622 (2%) | 0% | 6.3 | 1,004,381 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.46 per share. | 13 Feb 2025 | 158,921 | 2,576,701 (2%) | 0% | 8.5 | 1,344,472 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 211,160 | 2,787,861 (2%) | 0% | 6.3 | 1,334,531 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.50 per share. | 13 Feb 2025 | 211,160 | 2,576,701 (2%) | 0% | 8.5 | 1,794,860 | Common Stock |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 100,287 | 655,268 | - | - | Stock Option (right to buy) | |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 158,921 | 496,347 | - | - | Stock Option (right to buy) | |
| Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 211,160 | 285,187 | - | - | Stock Option (right to buy) | |
| Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.98 per share. | 18 Nov 2024 | 248 | 154,330 (0%) | 0% | 5.0 | 1,235 | Common Stock |
| Susan Bobulsky | Chief Commercial Officer, MRD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Susan Bobulsky | Chief Commercial Officer, MRD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 08 Oct 2024 | 5,000 | 253,290 (0%) | 0% | 2.0 | 9,900 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 4.50 per share. | 22 Aug 2024 | 26,922 | 139,365 (0%) | 0% | 4.5 | 121,079 | Common Stock |
| Kyle Piskel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 31,260 | 154,578 (0%) | 0% | 0 | Common Stock | |
| Peter M. Neupert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 12 Mar 2024 | 15,000 | 169,296 (0%) | 0% | 0.8 | 12,600 | Common Stock |
| Peter M. Neupert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 15,000 | 0 | - | - | Stock Option (right to buy) | |
| Michael J. Pellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 31,328 | 54,296 (0%) | 0% | 0 | Common Stock | |
| Michael J. Pellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 48,044 | 48,044 | - | - | Stock Option (right to buy) | |
| Peter M. Neupert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 48,044 | 48,044 | - | - | Stock Option (right to buy) | |
| Peter M. Neupert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 31,328 | 154,296 (0%) | 0% | 0 | Common Stock | |
| Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 48,044 | 48,044 | - | - | Stock Option (right to buy) | |
| Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 31,328 | 107,296 (0%) | 0% | 0 | Common Stock | |
| Michelle G. Burris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 31,328 | 51,955 (0%) | 0% | 0 | Common Stock | |
| Michelle G. Burris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 48,044 | 48,044 | - | - | Stock Option (right to buy) | |
| Chad Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 354,610 | 2,625,374 (2%) | 0% | 0 | Common Stock | |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 42,794 | 2,576,701 (2%) | 0% | 3.4 | 146,783 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 5,879 | 2,619,495 (2%) | 0% | 3.4 | 20,224 | Common Stock |
| Julie Rubinstein | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 175,000 | 511,824 (0%) | 0% | 0 | Common Stock | |
| Julie Rubinstein | President | Sale of securities on an exchange or to another person at price $ 3.56 per share. | 04 Mar 2024 | 13,490 | 472,754 (0%) | 0% | 3.6 | 48,024 | Common Stock |
| Julie Rubinstein | President | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 25,580 | 486,244 (0%) | 0% | 3.4 | 87,739 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 354,610 | 1,021,180 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 99,976 | 268,445 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 12,887 | 255,558 (0%) | 0% | 3.4 | 44,202 | Common Stock |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 1,813 | 253,745 (0%) | 0% | 3.4 | 6,237 | Common Stock |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 150,024 | 150,024 | - | - | Stock Option (right to buy) | |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 10,746 | 346,059 (0%) | 0% | 3.4 | 36,859 | Common Stock |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 132,979 | 356,805 (0%) | 0% | 0 | Common Stock | |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 18,644 | 327,415 (0%) | 0% | 3.4 | 64,135 | Common Stock |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 43,740 | 131,045 (0%) | 0% | 0 | Common Stock | |
| Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 7,727 | 123,318 (0%) | 0% | 3.4 | 26,504 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 60,010 | 60,010 | - | - | Stock Option (right to buy) | |
| Stacy L. Taylor | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 39,990 | 179,668 (0%) | 0% | 0 | Common Stock | |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 6,609 | 166,287 (0%) | 0% | 3.4 | 22,735 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 6,772 | 172,896 (0%) | 0% | 3.4 | 23,228 | Common Stock |
| Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 6,975 | 248,290 (0%) | 0% | 3.4 | 23,994 | Common Stock |
| Susan Bobulsky | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 6,016 | 255,265 (0%) | 0% | 3.4 | 20,635 | Common Stock |
| Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Susan Bobulsky | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 132,979 | 261,281 (0%) | 0% | 0 | Common Stock | |
| Einterz Owen Katey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 31,328 | 57,235 (0%) | 0% | 0 | Common Stock | |
| Einterz Owen Katey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 48,044 | 48,044 | - | - | Stock Option (right to buy) | |
| Tycho Peterson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 147,790 | 547,009 (0%) | 0% | 0 | Common Stock | |
| Tycho Peterson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 15,456 | 531,553 (0%) | 0% | 3.4 | 53,169 | Common Stock |
| Peter M. Neupert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2023 | 100,000 | 0 | - | - | Stock Option (right to buy) | |
| Peter M. Neupert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.84 per share. | 13 Dec 2023 | 100,000 | 122,968 (0%) | 0% | 0.8 | 84,000 | Common Stock |
| Nitin Sood | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 6.78 per share. | 07 Aug 2023 | 5,652 | 225,358 (0%) | 0% | 6.8 | 38,321 | Common Stock |
| Nitin Sood | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 6.54 per share. | 07 Aug 2023 | 10,550 | 214,808 (0%) | 0% | 6.5 | 68,997 | Common Stock |
| Tycho Peterson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.30 per share. | 20 Jun 2023 | 134,961 | 534,180 (0%) | 0% | 7.3 | 985,215 | Common Stock |
| Tycho Peterson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 134,961 | 447,868 | - | - | Stock Option (right to buy) | |
| Tycho Peterson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.14 per share. | 20 Jun 2023 | 64,961 | 399,219 (0%) | 0% | 8.1 | 528,783 | Common Stock |
| Tycho Peterson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.14 per share. | 20 Jun 2023 | 70,000 | 464,180 (0%) | 0% | 8.1 | 569,800 | Common Stock |
| Tycho Peterson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 15 Jun 2023 | 55,672 | 399,219 (0%) | 0% | 8.5 | 474,882 | Common Stock |
| Tycho Peterson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 14,328 | 582,829 | - | - | Stock Option (right to buy) | |
| Tycho Peterson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 15 Jun 2023 | 14,328 | 399,219 (0%) | 0% | 8.5 | 122,218 | Common Stock |
| Tycho Peterson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.30 per share. | 15 Jun 2023 | 14,328 | 413,547 (0%) | 0% | 7.3 | 104,594 | Common Stock |
| Tycho Peterson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.16 per share. | 02 Jun 2023 | 38,000 | 454,891 (0%) | 0% | 7.2 | 272,080 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.63 per share. | 10 Apr 2023 | 2,308 | 175,361 (0%) | 0% | 8.6 | 19,918 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.50 per share. | 10 Apr 2023 | 817 | 177,669 (0%) | 0% | 8.5 | 6,945 | Common Stock |
| Leslie L. Trigg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,775 | 25,907 (0%) | 0% | 0 | Common Stock | |
| Leslie L. Trigg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 23,329 | 23,329 | - | - | Stock Option (right to buy) | |
| Kevin T. Conroy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,775 | 22,968 (0%) | 0% | 0 | Common Stock | |
| Kevin T. Conroy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 23,329 | 23,329 | - | - | Stock Option (right to buy) | |
| Michael J. Pellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 23,329 | 23,329 | - | - | Stock Option (right to buy) | |
| Michael J. Pellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,775 | 22,968 (0%) | 0% | 0 | Common Stock | |
| Peter M. Neupert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,775 | 22,968 (0%) | 0% | 0 | Common Stock | |
| Peter M. Neupert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 23,329 | 23,329 | - | - | Stock Option (right to buy) | |
| Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,775 | 75,968 (0%) | 0% | 0 | Common Stock | |
| Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 23,329 | 23,329 | - | - | Stock Option (right to buy) | |
| Chad Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 354,610 | 2,270,764 (1%) | 0% | 0 | Common Stock | |
| Julie Rubinstein | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 132,979 | 359,492 (0%) | 0% | 0 | Common Stock | |
| Julie Rubinstein | President | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 22,668 | 336,824 (0%) | 0% | 8.6 | 194,265 | Common Stock |
| Julie Rubinstein | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Harlan Robins | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 354,610 | 666,570 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 128,599 | 128,599 | - | - | Stock Option (right to buy) | |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 85,697 | 175,285 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 6,816 | 168,469 (0%) | 0% | 8.6 | 58,413 | Common Stock |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 132,979 | 235,575 (0%) | 0% | 0 | Common Stock | |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 11,749 | 223,826 (0%) | 0% | 8.6 | 100,689 | Common Stock |
| Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 3,300 | 87,793 (0%) | 0% | 8.6 | 28,281 | Common Stock |
| Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 8.58 per share. | 06 Mar 2023 | 229 | 87,564 (0%) | 0% | 8.6 | 1,965 | Common Stock |
| Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 43,735 | 91,093 (0%) | 0% | 0 | Common Stock | |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 8.60 per share. | 06 Mar 2023 | 13,387 | 139,678 (0%) | 0% | 8.6 | 115,128 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 85,697 | 158,556 (0%) | 0% | 0 | Common Stock | |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 5,491 | 153,065 (0%) | 0% | 8.6 | 47,058 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 128,599 | 128,599 | - | - | Stock Option (right to buy) | |
| R Mark Adams | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 88,652 | 202,170 (0%) | 0% | 0 | Common Stock | |
| R Mark Adams | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 133,033 | 133,033 | - | - | Stock Option (right to buy) | |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.60 per share. | 06 Mar 2023 | 17,155 | 178,486 (0%) | 0% | 8.6 | 147,533 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 6,529 | 195,641 (0%) | 0% | 8.6 | 55,954 | Common Stock |
| Einterz Owen Katey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,775 | 25,907 (0%) | 0% | 0 | Common Stock | |
| Einterz Owen Katey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 23,329 | 23,329 | - | - | Stock Option (right to buy) | |
| Nitin Sood | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 132,979 | 247,484 (0%) | 0% | 0 | Common Stock | |
| Nitin Sood | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 8.60 per share. | 06 Mar 2023 | 9,813 | 231,010 (0%) | 0% | 8.6 | 84,392 | Common Stock |
| Nitin Sood | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 6,661 | 240,823 (0%) | 0% | 8.6 | 57,085 | Common Stock |
| Nitin Sood | Chief Commercial Officer, MRD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 199,549 | 199,549 | - | - | Stock Option (right to buy) | |
| Tycho Peterson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 118,203 | 492,891 (0%) | 0% | 0 | Common Stock | |
| Tycho Peterson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 177,377 | 177,377 | - | - | Stock Option (right to buy) | |
| Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 53,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 02 Feb 2023 | 53,000 | 61,193 (0%) | 0% | 0.5 | 23,850 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.58 per share. | 09 Jan 2023 | 2,130 | 113,518 (0%) | 0% | 8.6 | 18,275 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.50 per share. | 09 Jan 2023 | 995 | 115,648 (0%) | 0% | 8.5 | 8,458 | Common Stock |
| Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 8.87 per share. | 16 Nov 2022 | 307 | 47,358 (0%) | 0% | 8.9 | 2,723 | Common Stock |
| Nitin Sood | Chief Commercial Officer, MRD | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 01 Nov 2022 | 31,066 | 114,505 (0%) | 0% | 8 | 248,528 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 7.61 per share. | 07 Oct 2022 | 841 | 118,927 (0%) | 0% | 7.6 | 6,400 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 7.13 per share. | 07 Oct 2022 | 2,284 | 116,643 (0%) | 0% | 7.1 | 16,285 | Common Stock |
| Tycho Peterson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 597,157 | 597,157 | - | - | Stock Option (Right to Buy) | |
| Tycho Peterson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 374,688 | 374,688 (0%) | 0% | 0 | Common Stock | |
| Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.43 per share. | 08 Mar 2022 | 3,350 | 17,171 (0%) | 0% | 11.4 | 38,291 | Common Stock |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 11.44 per share. | 08 Mar 2022 | 3,582 | 89,588 (0%) | 0% | 11.4 | 40,978 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 11.44 per share. | 08 Mar 2022 | 2,387 | 72,859 (0%) | 0% | 11.4 | 27,307 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 12.22 per share. | 07 Mar 2022 | 500 | 1,930,469 (1%) | 0% | 12.2 | 6,110 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 07 Mar 2022 | 14,815 | 1,930,969 (1%) | 0% | 6.3 | 93,631 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 11.38 per share. | 07 Mar 2022 | 14,815 | 1,916,154 (1%) | 0% | 11.4 | 168,595 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 07 Mar 2022 | 14,815 | 1,930,969 (1%) | 0% | 6.3 | 93,631 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 11.53 per share. | 07 Mar 2022 | 14,315 | 1,916,154 (1%) | 0% | 11.5 | 165,052 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 14,815 | 755,555 | - | - | Stock Option (Right to Buy) | |
| Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 14,815 | 770,370 | - | - | Stock Option (Right to Buy) | |
| Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 14,815 | 785,185 | - | - | Stock Option (Right to Buy) | |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 12.46 per share. | 07 Mar 2022 | 14,815 | 1,916,154 (1%) | 0% | 12.5 | 184,595 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 07 Mar 2022 | 14,815 | 1,930,969 (1%) | 0% | 6.3 | 93,631 | Common Stock |
| Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 07 Mar 2022 | 2,373 | 20,521 (0%) | 0% | 12.0 | 28,500 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 4,424 | 1,916,154 (1%) | 0% | 12.0 | 53,132 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 247,117 | 1,920,578 (1%) | 0% | 0 | Common Stock | |
| Julie Rubinstein | President | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 4,613 | 226,513 (0%) | 0% | 12.0 | 55,402 | Common Stock |
| Julie Rubinstein | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 185,338 | 231,126 (0%) | 0% | 0 | Common Stock | |
| Julie Rubinstein | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 463,344 | 463,344 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 617,792 | 617,792 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 4,517 | 311,960 (0%) | 0% | 12.0 | 54,249 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 247,117 | 316,477 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 185,338 | 185,338 | - | - | Stock Option (Right to Buy) | |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 74,135 | 94,739 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 1,569 | 93,170 (0%) | 0% | 12.0 | 18,844 | Common Stock |
| Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 2,670 | 102,596 (0%) | 0% | 12.0 | 32,067 | Common Stock |
| Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 82,372 | 105,266 (0%) | 0% | 0 | Common Stock | |
| Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 205,931 | 205,931 | - | - | Stock Option (Right to Buy) | |
| Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 102,965 | 102,965 | - | - | Stock Option (Right to Buy) | |
| Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 41,186 | 47,885 (0%) | 0% | 0 | Common Stock | |
| Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 220 | 47,665 (0%) | 0% | 12.0 | 2,642 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 1,569 | 75,246 (0%) | 0% | 12.0 | 18,844 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 154,448 | 154,448 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 61,779 | 76,815 (0%) | 0% | 0 | Common Stock | |
| R Mark Adams | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 185,338 | 185,338 | - | - | Stock Option (Right to Buy) | |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 1,244 | 123,724 (0%) | 0% | 12.0 | 14,940 | Common Stock |
| R Mark Adams | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 74,135 | 124,968 (0%) | 0% | 0 | Common Stock | |
| Nitin Sood | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 65,898 | 163,111 (0%) | 0% | 0 | Common Stock | |
| Nitin Sood | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 164,745 | 164,745 | - | - | Stock Option (Right to Buy) | |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.32 per share. | 07 Jan 2022 | 1,021 | 50,833 (0%) | 0% | 23.3 | 23,810 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 22 Dec 2021 | 10,000 | 31,604 (0%) | 0% | 7.3 | 72,700 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 10,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 22 Dec 2021 | 10,000 | 21,604 (0%) | 0% | 30 | 300,000 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 22 Dec 2021 | 15,338 | 15,036 (0%) | 0% | 30 | 460,140 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 22 Dec 2021 | 5,208 | 30,374 (0%) | 0% | 7.8 | 40,622 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 22 Dec 2021 | 10,130 | 25,166 (0%) | 0% | 6.6 | 66,352 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 5,208 | 17,709 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 10,130 | 5,313 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.05 per share. | 17 Nov 2021 | 3,700 | 69,360 (0%) | 0% | 32.1 | 118,585 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2021 | 300 | 284,800 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2021 | 3,700 | 285,100 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.36 per share. | 17 Nov 2021 | 300 | 69,360 (0%) | 0% | 31.4 | 9,408 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 17 Nov 2021 | 300 | 69,660 (0%) | 0% | 6.6 | 1,965 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 17 Nov 2021 | 3,700 | 73,060 (0%) | 0% | 6.6 | 24,235 | Common Stock |
| Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 9,592 | 9,592 | - | - | Stock Option (Right to Buy) | |
| Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 3,837 | 6,699 (0%) | 0% | 0 | Common Stock | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.03 per share. | 09 Nov 2021 | 5,000 | 21,604 (0%) | 0% | 36.0 | 180,150 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 5,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 5,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.93 per share. | 09 Nov 2021 | 5,000 | 21,604 (0%) | 0% | 33.9 | 169,650 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 09 Nov 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 09 Nov 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 19 Oct 2021 | 3,700 | 73,060 (0%) | 0% | 6.6 | 24,235 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2021 | 3,700 | 288,800 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2021 | 3,700 | 292,500 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2021 | 3,800 | 296,200 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.73 per share. | 19 Oct 2021 | 3,700 | 69,360 (0%) | 0% | 33.7 | 124,801 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.71 per share. | 19 Oct 2021 | 3,700 | 69,360 (0%) | 0% | 33.7 | 124,727 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 19 Oct 2021 | 3,700 | 73,060 (0%) | 0% | 6.6 | 24,235 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.76 per share. | 19 Oct 2021 | 3,500 | 69,360 (0%) | 0% | 33.8 | 118,160 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.91 per share. | 19 Oct 2021 | 300 | 72,860 (0%) | 0% | 32.9 | 9,873 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 19 Oct 2021 | 3,800 | 73,160 (0%) | 0% | 6.6 | 24,890 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.47 per share. | 07 Oct 2021 | 1,324 | 53,655 (0%) | 0% | 32.5 | 42,990 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 33.67 per share. | 07 Oct 2021 | 1,801 | 51,854 (0%) | 0% | 33.7 | 60,640 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2021 | 3,895 | 74,005 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2021 | 3,895 | 77,900 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.96 per share. | 06 Oct 2021 | 3,895 | 69,360 (0%) | 0% | 33.0 | 128,379 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 06 Oct 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.68 per share. | 06 Oct 2021 | 3,695 | 69,360 (0%) | 0% | 33.7 | 124,448 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 06 Oct 2021 | 200 | 73,055 (0%) | 0% | 32.5 | 6,500 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 06 Oct 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 06 Oct 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.27 per share. | 06 Oct 2021 | 3,895 | 69,360 (0%) | 0% | 32.3 | 125,692 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2021 | 3,895 | 70,110 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.51 per share. | 05 Oct 2021 | 5,000 | 21,604 (0%) | 0% | 32.5 | 162,550 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 5,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 5,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.30 per share. | 05 Oct 2021 | 5,000 | 21,604 (0%) | 0% | 32.3 | 161,500 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 05 Oct 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 05 Oct 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.89 per share. | 13 Sep 2021 | 900 | 69,360 (0%) | 0% | 37.9 | 34,101 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 3,895 | 81,795 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 3,895 | 85,690 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 3,895 | 89,585 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.23 per share. | 13 Sep 2021 | 900 | 69,360 (0%) | 0% | 37.2 | 33,507 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.52 per share. | 13 Sep 2021 | 2,995 | 70,260 (0%) | 0% | 36.5 | 109,377 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Sep 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Sep 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.36 per share. | 13 Sep 2021 | 1,100 | 69,360 (0%) | 0% | 37.4 | 41,096 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.49 per share. | 13 Sep 2021 | 2,795 | 70,460 (0%) | 0% | 36.5 | 101,990 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Sep 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.39 per share. | 13 Sep 2021 | 2,995 | 70,260 (0%) | 0% | 37.4 | 111,983 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 07 Sep 2021 | 9,375 | 30,979 (0%) | 0% | 6.5 | 61,406 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 5,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 9,375 | 65,625 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.01 per share. | 07 Sep 2021 | 5,000 | 21,604 (0%) | 0% | 39.0 | 195,050 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 07 Sep 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.71 per share. | 07 Sep 2021 | 9,375 | 21,604 (0%) | 0% | 39.7 | 372,281 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 07 Sep 2021 | 495 | 15,036 (0%) | 0% | 40 | 19,800 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 495 | 15,443 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 07 Sep 2021 | 495 | 15,531 (0%) | 0% | 6.5 | 3,242 | Common Stock |
| Nitin Sood | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 162,022 | 162,022 | - | - | Stock Option (Right to Buy) | |
| Nitin Sood | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 97,213 | 97,213 (0%) | 0% | 0 | Common Stock | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 10 Aug 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 10 Aug 2021 | 5,000 | 26,604 (0%) | 0% | 6.6 | 32,750 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 10 Aug 2021 | 5,000 | 21,604 (0%) | 0% | 35 | 175,000 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 10,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 5,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.47 per share. | 10 Aug 2021 | 1,262 | 21,604 (0%) | 0% | 34.5 | 43,501 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.48 per share. | 10 Aug 2021 | 8,738 | 22,866 (0%) | 0% | 33.5 | 292,548 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.70 per share. | 19 Jul 2021 | 1,273 | 71,982 (0%) | 0% | 36.7 | 46,719 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2021 | 3,895 | 105,165 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2021 | 3,895 | 109,060 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2021 | 3,895 | 112,955 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.11 per share. | 19 Jul 2021 | 2,495 | 69,360 (0%) | 0% | 38.1 | 95,084 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.29 per share. | 19 Jul 2021 | 1,400 | 71,855 (0%) | 0% | 37.3 | 52,206 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Jul 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.82 per share. | 19 Jul 2021 | 2,595 | 69,360 (0%) | 0% | 37.8 | 98,143 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.81 per share. | 19 Jul 2021 | 1,300 | 71,955 (0%) | 0% | 36.8 | 47,853 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Jul 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.33 per share. | 19 Jul 2021 | 2,622 | 69,360 (0%) | 0% | 37.3 | 97,879 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Jul 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.55 per share. | 19 Jul 2021 | 651 | 9,809 (0%) | 0% | 22.5 | 14,680 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2021 | 651 | 104,393 | - | - | Stock Option (Right to Buy) | |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Sale of securities on an exchange or to another person at price $ 36.12 per share. | 19 Jul 2021 | 651 | 9,158 (0%) | 0% | 36.1 | 23,514 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 38.24 per share. | 12 Jul 2021 | 1,501 | 1,716,960 (1%) | 0% | 38.2 | 57,398 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 36.30 per share. | 07 Jul 2021 | 2,254 | 54,979 (0%) | 0% | 36.3 | 81,820 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 39.42 per share. | 07 Jul 2021 | 871 | 57,233 (0%) | 0% | 39.4 | 34,335 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.83 per share. | 06 Jul 2021 | 10,000 | 21,604 (0%) | 0% | 38.8 | 388,300 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 10,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 10,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.20 per share. | 06 Jul 2021 | 3,514 | 21,604 (0%) | 0% | 39.2 | 137,749 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.17 per share. | 06 Jul 2021 | 6,486 | 25,118 (0%) | 0% | 38.2 | 247,571 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 06 Jul 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 06 Jul 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 42.13 per share. | 30 Jun 2021 | 395 | 15,036 (0%) | 0% | 42.1 | 16,641 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2021 | 1,354 | 43,334 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2021 | 1,771 | 15,938 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2021 | 1,042 | 22,917 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 41.35 per share. | 30 Jun 2021 | 3,772 | 15,431 (0%) | 0% | 41.3 | 155,972 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.71 per share. | 30 Jun 2021 | 1,354 | 19,203 (0%) | 0% | 31.7 | 42,935 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 30 Jun 2021 | 1,771 | 17,849 (0%) | 0% | 6.5 | 11,600 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 30 Jun 2021 | 1,042 | 16,078 (0%) | 0% | 7.8 | 8,128 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 17 Jun 2021 | 1,041 | 16,077 (0%) | 0% | 7.8 | 8,120 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 1,354 | 44,688 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 1,771 | 17,709 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 1,041 | 23,959 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 17 Jun 2021 | 4,166 | 15,036 (0%) | 0% | 40 | 166,640 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.71 per share. | 17 Jun 2021 | 1,354 | 19,202 (0%) | 0% | 31.7 | 42,935 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 17 Jun 2021 | 1,771 | 17,848 (0%) | 0% | 6.5 | 11,600 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.55 per share. | 17 Jun 2021 | 651 | 9,809 (0%) | 0% | 22.5 | 14,680 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Sale of securities on an exchange or to another person at price $ 39.80 per share. | 17 Jun 2021 | 1,301 | 9,158 (0%) | 0% | 39.8 | 51,780 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.55 per share. | 17 Jun 2021 | 1,301 | 10,459 (0%) | 0% | 22.6 | 29,338 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 17 Jun 2021 | 651 | 9,158 (0%) | 0% | 40 | 26,040 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 1,301 | 105,344 | - | - | Stock Option (Right to Buy) | |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 651 | 106,345 | - | - | Stock Option (Right to Buy) | |
| R Mark Adams | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 14,583 | 35,417 | - | - | Stock Option (Right to Buy) | |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 17 Jun 2021 | 14,583 | 58,104 (0%) | 0% | 40 | 583,320 | Common Stock |
| R Mark Adams | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.10 per share. | 17 Jun 2021 | 14,583 | 72,687 (0%) | 0% | 28.1 | 409,782 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 38.22 per share. | 15 Jun 2021 | 19,100 | 1,729,361 (1%) | 0% | 38.2 | 730,002 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 39.76 per share. | 15 Jun 2021 | 4,255 | 1,718,461 (1%) | 0% | 39.8 | 169,179 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 38.55 per share. | 15 Jun 2021 | 1,000 | 1,722,716 (1%) | 0% | 38.6 | 38,550 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 38.13 per share. | 15 Jun 2021 | 4,745 | 1,723,716 (1%) | 0% | 38.1 | 180,927 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 39.23 per share. | 15 Jun 2021 | 900 | 1,728,461 (1%) | 0% | 39.2 | 35,307 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 38.77 per share. | 14 Jun 2021 | 8,914 | 58,104 (0%) | 0% | 38.8 | 345,596 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.90 per share. | 08 Jun 2021 | 8,401 | 23,203 (0%) | 0% | 36.9 | 309,997 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 10,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 10,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.60 per share. | 08 Jun 2021 | 10,000 | 21,604 (0%) | 0% | 35.6 | 356,000 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 08 Jun 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.85 per share. | 08 Jun 2021 | 1,599 | 21,604 (0%) | 0% | 37.8 | 60,522 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 08 Jun 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 18 May 2021 | 651 | 9,158 (0%) | 0% | 35 | 22,785 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 651 | 106,996 | - | - | Stock Option (Right to Buy) | |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.55 per share. | 18 May 2021 | 651 | 9,809 (0%) | 0% | 22.5 | 14,680 | Common Stock |
| Henning Thorsen | SVP, Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 72,653 | 72,653 | - | - | Stock Option (Right to Buy) | |
| Henning Thorsen | SVP, Commercial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 29,061 | 29,061 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2021 | 2,000 | 151,000 | - | - | Stock Option (Right To Buy) | |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 33.80 per share. | 14 May 2021 | 2,000 | 20,604 (0%) | 0% | 33.8 | 67,600 | Common Stock |
| Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 14 May 2021 | 2,000 | 22,604 (0%) | 0% | 7.8 | 15,600 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 11 May 2021 | 7,031 | 21,604 (0%) | 0% | 31.8 | 223,867 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.63 per share. | 11 May 2021 | 10,000 | 21,604 (0%) | 0% | 32.6 | 326,300 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 11 May 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.81 per share. | 11 May 2021 | 2,969 | 28,635 (0%) | 0% | 30.8 | 91,475 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 11 May 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.80 per share. | 04 May 2021 | 700 | 69,360 (0%) | 0% | 36.8 | 25,760 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2021 | 3,895 | 136,325 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 04 May 2021 | 3,895 | 73,255 (0%) | 0% | 6.3 | 24,616 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.99 per share. | 04 May 2021 | 3,195 | 70,060 (0%) | 0% | 36.0 | 114,988 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 1,770 | 19,480 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 1,042 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 41.93 per share. | 30 Apr 2021 | 4,166 | 15,036 (0%) | 0% | 41.9 | 174,680 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.71 per share. | 30 Apr 2021 | 1,354 | 19,202 (0%) | 0% | 31.7 | 42,935 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 30 Apr 2021 | 1,770 | 17,848 (0%) | 0% | 6.6 | 11,594 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 30 Apr 2021 | 1,042 | 16,078 (0%) | 0% | 7.8 | 8,128 | Common Stock |
| Stacy L. Taylor | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 1,354 | 46,042 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 20 Apr 2021 | 11,685 | 81,045 (0%) | 0% | 6.3 | 73,849 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2021 | 7,790 | 140,220 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2021 | 7,790 | 148,010 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2021 | 11,685 | 155,800 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 43.59 per share. | 20 Apr 2021 | 3,510 | 69,360 (0%) | 0% | 43.6 | 153,001 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.85 per share. | 20 Apr 2021 | 4,280 | 72,870 (0%) | 0% | 42.9 | 183,398 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 20 Apr 2021 | 7,790 | 77,150 (0%) | 0% | 6.3 | 49,233 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.79 per share. | 20 Apr 2021 | 5,200 | 69,360 (0%) | 0% | 41.8 | 217,308 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.17 per share. | 20 Apr 2021 | 2,090 | 74,560 (0%) | 0% | 41.2 | 86,045 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.85 per share. | 20 Apr 2021 | 500 | 76,650 (0%) | 0% | 39.9 | 19,925 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 20 Apr 2021 | 7,790 | 77,150 (0%) | 0% | 6.3 | 49,233 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.35 per share. | 20 Apr 2021 | 3,000 | 69,360 (0%) | 0% | 41.4 | 124,050 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.24 per share. | 20 Apr 2021 | 8,685 | 72,360 (0%) | 0% | 40.2 | 349,484 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.55 per share. | 19 Apr 2021 | 1,301 | 10,459 (0%) | 0% | 22.6 | 29,338 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 1,301 | 107,647 | - | - | Stock Option (Right to Buy) | |
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | Sale of securities on an exchange or to another person at price $ 41.25 per share. | 19 Apr 2021 | 1,301 | 9,158 (0%) | 0% | 41.2 | 53,666 | Common Stock |
| R Mark Adams | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 42.34 per share. | 07 Apr 2021 | 3,586 | 67,018 (0%) | 0% | 42.3 | 151,831 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2021 | 10,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 06 Apr 2021 | 10,000 | 31,604 (0%) | 0% | 6.3 | 63,200 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 06 Apr 2021 | 10,000 | 31,604 (0%) | 0% | 6.3 | 63,200 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.95 per share. | 06 Apr 2021 | 10,000 | 21,604 (0%) | 0% | 41.0 | 409,500 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.59 per share. | 06 Apr 2021 | 9,194 | 22,410 (0%) | 0% | 41.6 | 382,378 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.34 per share. | 06 Apr 2021 | 806 | 21,604 (0%) | 0% | 42.3 | 34,126 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2021 | 10,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.78 per share. | 06 Apr 2021 | 100 | 1,748,461 (1%) | 0% | 43.8 | 4,378 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.00 per share. | 06 Apr 2021 | 1,957 | 1,748,561 (1%) | 0% | 43 | 84,151 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 42.04 per share. | 06 Apr 2021 | 2,943 | 1,750,518 (1%) | 0% | 42.0 | 123,724 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 41.45 per share. | 06 Apr 2021 | 1,100 | 1,753,461 (1%) | 0% | 41.5 | 45,595 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 40.61 per share. | 06 Apr 2021 | 3,900 | 1,754,561 (1%) | 0% | 40.6 | 158,379 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.08 per share. | 06 Apr 2021 | 1,200 | 1,758,461 (1%) | 0% | 43.1 | 51,696 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 42.48 per share. | 06 Apr 2021 | 2,200 | 1,759,661 (1%) | 0% | 42.5 | 93,456 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 41.08 per share. | 06 Apr 2021 | 1,600 | 1,761,861 (1%) | 0% | 41.1 | 65,728 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 23 Mar 2021 | 7,790 | 77,150 (0%) | 0% | 6.3 | 49,233 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 5,290 | 167,485 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 6,395 | 172,775 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 7,790 | 179,170 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.72 per share. | 23 Mar 2021 | 1,481 | 69,360 (0%) | 0% | 38.7 | 57,344 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.13 per share. | 23 Mar 2021 | 3,809 | 70,841 (0%) | 0% | 38.1 | 145,237 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 23 Mar 2021 | 5,290 | 74,650 (0%) | 0% | 6.3 | 33,433 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.76 per share. | 23 Mar 2021 | 400 | 69,360 (0%) | 0% | 41.8 | 16,704 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.33 per share. | 23 Mar 2021 | 4,175 | 69,760 (0%) | 0% | 40.3 | 168,378 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.43 per share. | 23 Mar 2021 | 1,820 | 73,935 (0%) | 0% | 39.4 | 71,763 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 23 Mar 2021 | 6,395 | 75,755 (0%) | 0% | 6.3 | 40,416 | Common Stock |
| Harlan Robins | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.93 per share. | 23 Mar 2021 | 7,790 | 69,360 (0%) | 0% | 41.9 | 326,635 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, immunoSEQ Dx | Sale of securities on an exchange or to another person at price $ 45.32 per share. | 18 Mar 2021 | 1,739 | 9,158 (0%) | 0% | 45.3 | 78,811 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, immunoSEQ Dx | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.55 per share. | 18 Mar 2021 | 16,052 | 25,210 (0%) | 0% | 22.6 | 361,973 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, immunoSEQ Dx | Sale of securities on an exchange or to another person at price $ 43.04 per share. | 18 Mar 2021 | 8,342 | 16,868 (0%) | 0% | 43.0 | 359,040 | Common Stock |
| Jyoti Palaniappan | SVP, Diagnostics, immunoSEQ Dx | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2021 | 16,052 | 108,948 | - | - | Stock Option (Right to Buy) | |
| Jyoti Palaniappan | SVP, Diagnostics, immunoSEQ Dx | Sale of securities on an exchange or to another person at price $ 43.83 per share. | 18 Mar 2021 | 5,971 | 10,897 (0%) | 0% | 43.8 | 261,709 | Common Stock |
| Leslie L. Trigg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 4,443 | 4,443 (0%) | 0% | 0 | Common Stock | |
| Leslie L. Trigg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 11,109 | 11,109 | - | - | Stock Option (Right to Buy) | |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.22 per share. | 17 Mar 2021 | 1,901 | 1,776,560 (1%) | 0% | 43.2 | 82,161 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 42.48 per share. | 17 Mar 2021 | 100 | 1,763,461 (1%) | 0% | 42.5 | 4,248 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 41.96 per share. | 17 Mar 2021 | 4,900 | 1,763,561 (1%) | 0% | 42.0 | 205,604 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.78 per share. | 17 Mar 2021 | 470 | 1,768,461 (1%) | 0% | 43.8 | 20,577 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 42.81 per share. | 17 Mar 2021 | 2,604 | 1,768,931 (1%) | 0% | 42.8 | 111,477 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 41.90 per share. | 17 Mar 2021 | 1,926 | 1,771,535 (1%) | 0% | 41.9 | 80,699 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 17 Mar 2021 | 1,804 | 1,773,461 (1%) | 0% | 45.3 | 81,631 | Common Stock |
| Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 44.03 per share. | 17 Mar 2021 | 1,295 | 1,775,265 (1%) | 0% | 44.0 | 57,019 | Common Stock |
| Einterz Owen Katey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 4,443 | 4,443 (0%) | 0% | 0 | Common Stock | |
| Einterz Owen Katey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 11,109 | 11,109 | - | - | Stock Option (Right to Buy) | |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 41.57 per share. | 15 Mar 2021 | 878 | 21,726 (0%) | 0% | 41.6 | 36,498 | Common Stock |
| Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 2,000 | 155,000 | - | - | Stock Option (Right To Buy) | |
| Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 42.03 per share. | 15 Mar 2021 | 1,122 | 20,604 (0%) | 0% | 42.0 | 47,158 | Common Stock |
| Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 15 Mar 2021 | 2,000 | 22,604 (0%) | 0% | 7.8 | 15,600 | Common Stock |
| Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.71 per share. | 15 Mar 2021 | 1,354 | 24,248 (0%) | 0% | 31.7 | 42,935 | Common Stock |
| Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 1,354 | 47,396 | - | - | Stock Option (Right to Buy) | |
| Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 41.85 per share. | 15 Mar 2021 | 1,014 | 22,894 (0%) | 0% | 41.9 | 42,436 | Common Stock |
| Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 41.22 per share. | 15 Mar 2021 | 340 | 23,908 (0%) | 0% | 41.2 | 14,015 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 10 Mar 2021 | 10,000 | 31,604 (0%) | 0% | 6.3 | 63,200 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 10,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.54 per share. | 10 Mar 2021 | 10,000 | 21,604 (0%) | 0% | 42.5 | 425,400 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2021 | 10,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 09 Mar 2021 | 10,000 | 31,064 (0%) | 0% | 6.3 | 63,200 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.02 per share. | 09 Mar 2021 | 7,110 | 23,954 (0%) | 0% | 40.0 | 284,542 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.79 per share. | 09 Mar 2021 | 2,890 | 21,064 (0%) | 0% | 40.8 | 117,883 | Common Stock |
| Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 44.56 per share. | 08 Mar 2021 | 2,000 | 1,504 (0%) | 0% | 44.6 | 89,120 | Common Stock |
| Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 08 Mar 2021 | 2,000 | 3,504 (0%) | 0% | 0.5 | 900 | Common Stock |
| Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 2,000 | 53,000 | - | - | Stock Option (Right to Buy) | |
| Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 44.56 per share. | 08 Mar 2021 | 2,000 | 0 (0%) | 0% | 44.6 | 89,120 | Common Stock |
| Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 08 Mar 2021 | 2,000 | 2,000 (0%) | 0% | 0.5 | 900 | Common Stock |
| Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 2,000 | 53,000 | - | - | Stock Option (Right to Buy) | |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.22 per share. | 08 Mar 2021 | 75,000 | 12,805,795 (10%) | 0% | 39.2 | 2,941,163 | Common Stock |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.97 per share. | 08 Mar 2021 | 33,600 | 12,772,195 (10%) | 0% | 40.0 | 1,343,039 | Common Stock |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 38.22 per share. | 08 Mar 2021 | 234,295 | 12,880,795 (10%) | 0% | 38.2 | 8,954,310 | Common Stock |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 41.16 per share. | 08 Mar 2021 | 34,302 | 12,365,090 (9%) | 0% | 41.2 | 1,411,887 | Common Stock |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 41.47 per share. | 08 Mar 2021 | 25,732 | 12,339,358 (9%) | 0% | 41.5 | 1,067,037 | Common Stock |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 42.38 per share. | 08 Mar 2021 | 30,268 | 12,309,090 (9%) | 0% | 42.4 | 1,282,664 | Common Stock |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 40.42 per share. | 08 Mar 2021 | 215,698 | 12,399,392 (9%) | 0% | 40.4 | 8,719,333 | Common Stock |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 41.62 per share. | 08 Mar 2021 | 85,911 | 12,615,090 (9%) | 0% | 41.6 | 3,575,753 | Common Stock |
| David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 41.21 per share. | 08 Mar 2021 | 71,194 | 12,701,001 (10%) | 0% | 41.2 | 2,933,641 | Common Stock |
| Chad M. Cohen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 20,604 | 21,604 (0%) | 0% | 0 | Common Stock | |
| Chad M. Cohen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 51,511 | 51,511 | - | - | Stock Option (Right to Buy) | |
| Chad Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 68,681 | 1,778,461 (1%) | 0% | 0 | Common Stock | |
| Chad Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 171,703 | 171,703 | - | - | Stock Option (Right to Buy) | |
| Julie Rubinstein | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 45,788 | 45,788 (0%) | 0% | 0 | Common Stock | |
| Julie Rubinstein | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 114,469 | 114,469 | - | - | Stock Option (Right to Buy) | |
| Harlan Robins | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 68,681 | 69,360 (0%) | 0% | 0 | Common Stock | |
| Harlan Robins | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 171,703 | 171,703 | - | - | Stock Option (Right to Buy) | |
| Lance Baldo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 57,234 | 57,234 | - | - | Stock Option (Right to Buy) | |
| Lance Baldo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 22,894 | 22,894 (0%) | 0% | 0 | Common Stock | |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 51,511 | 51,511 | - | - | Stock Option (Right to Buy) | |
| Francis Lo | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 20,604 | 20,604 (0%) | 0% | 0 | Common Stock | |
| Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 22,894 | 22,894 (0%) | 0% | 0 | Common Stock | |
| Sharon Benzeno | Chief Business Development Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 57,234 | 57,234 | - | - | Stock Option (Right to Buy) | |
| Stacy L. Taylor | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 13,736 | 15,036 (0%) | 0% | 0 | Common Stock | |
| Stacy L. Taylor | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 34,341 | 34,341 | - | - | Stock Option (Right to Buy) | |
| Jyoti Palaniappan | SVP, Diagnostics, immunoSEQ Dx | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 22,894 | 22,894 | - | - | Stock Option (Right to Buy) | |
| Jyoti Palaniappan | SVP, Diagnostics, immunoSEQ Dx | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 9,158 | 9,158 (0%) | 0% | 0 | Common Stock | |
| R Mark Adams | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 20,604 | 70,604 (0%) | 0% | 0 | Common Stock | |
| R Mark Adams | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 51,511 | 51,511 | - | - | Stock Option (Right to Buy) | |
| Susan Bobulsky | SVP, Diagnostics, clonoSEQ | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 9,158 | 9,158 (0%) | 0% | 0 | Common Stock | |
| Susan Bobulsky | SVP, Diagnostics, clonoSEQ | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 22,894 | 22,894 | - | - | Stock Option (Right to Buy) | |
| Michael J. Pellini | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 20,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Pellini | Director | Sale of securities on an exchange or to another person at price $ 57.80 per share. | 01 Mar 2021 | 20,000 | 1,504 (0%) | 0% | 57.8 | 1,156,000 | Common Stock |
| Michael J. Pellini | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Mar 2021 | 20,000 | 21,504 (0%) | 0% | 6.6 | 131,000 | Common Stock |
| Julie Rubinstein | President | Sale of securities on an exchange or to another person at price $ 58.64 per share. | 01 Mar 2021 | 9,471 | 845 (0%) | 0% | 58.6 | 555,379 | Common Stock |
| Julie Rubinstein | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 15,000 | 225,325 | - | - | Stock Option (Right to Buy) | |
| Julie Rubinstein | President | Sale of securities on an exchange or to another person at price $ 58.99 per share. | 01 Mar 2021 | 845 | 0 (0%) | 0% | 59.0 | 49,847 | Common Stock |
| Julie Rubinstein | President | Sale of securities on an exchange or to another person at price $ 57.54 per share. | 01 Mar 2021 | 4,684 | 10,316 (0%) | 0% | 57.5 | 269,517 | Common Stock |
| Julie Rubinstein | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Mar 2021 | 15,000 | 15,000 (0%) | 0% | 6.6 | 98,250 | Common Stock |
| Sharon Benzeno | Chief Business Development Off | Sale of securities on an exchange or to another person at price $ 57.57 per share. | 01 Mar 2021 | 6,210 | 561 (0%) | 0% | 57.6 | 357,510 | Common Stock |
| Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 01 Mar 2021 | 1,563 | 6,771 (0%) | 0% | 7.3 | 11,363 | Common Stock |
| Sharon Benzeno | Chief Business Development Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Mar 2021 | 2,604 | 5,208 (0%) | 0% | 6.5 | 17,056 | Common Stock |